Is it important for MDs to consider taking a more prominent role in the process of developing and getting drugs to market, either on the operating side or the investing side? How can we change and fix financial incentives in drug development? In this episode, we answer all these questions and more with our guest, David Kaufman, M.D.

David is a Partner at Third Rock Ventures, a leading healthcare venture firm that specializes in company creation rather than the traditional venture investing model.

David has an MD from Cornell University, and a PHD in immunology and molecular virology from Rockefeller University.